VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024
March 28 2024 - 8:02AM
Business Wire
VarmX, a biotech company focusing on the development of
innovative approaches for the reversal of anticoagulation, today
announces that it will be attending the LSX World Congress (29-30
April) and presenting at Bio€quity Europe (12-14 May).
The LSX World Congress is the leading partnering, strategy and
investment event in Europe, with 1:1 partnering at its core. VarmX
will be attending to interact with investors and other innovative
biopharmaceutical companies, and Martijn Negen, VarmX’s SVP Global
Commercial Strategy & Business Development, will be
participating in a panel discussion: Empowering Emerging Biotechs:
Enhancing the Path to Commercialisation.
Bio€quity Europe is a key biopartnering event for the biotech
industry in Europe, organised by BioCentury. Martijn Negen, VarmX’s
SVP Global Commercial Strategy & Business Development, has been
selected by the conference organisers to present at this esteemed
event.
If you are interested in meeting with the VarmX Team at either
of these upcoming events, or to get further information, please
contact: info@varmx.com.
Notes to Editors
About VarmX VarmX is a spin-off from the Leiden
University Medical Center (LUMC), founded in 2016 by Professor
Pieter Reitsma, a world leading expert in hemostasis and
thrombosis. VarmX’s lead compound VMX-C001 is a modified
recombinant blood factor X. The compound is being developed for the
treatment of severe spontaneous bleeding and for the prevention of
bleeding during urgent surgery in patients taking oral factor Xa
inhibitors (FXa DOACs) as anticoagulation therapy. The Company is
supported by a strong syndicate of investors including Sound
Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef,
Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures
and InnovationQuarter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328882295/en/
Instinctif Partners (media enquiries) Melanie
Toyne-Sewell / Katie Duffell Tel: +44 20 7457 2020 Email:
VarmX@instinctif.com